Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ETTX Entasis Therapeutics	$2.19	$2.19	$1.40 ▼ $3.88	$104.80M	1.33	239,104 shs	800 shs
KMDA Kamada	$6.94 -0.1%	$6.63	$4.74 ▼ $9.16	$399.09M	0.94	93,125 shs	71,600 shs
RIGL Rigel Pharmaceuticals	$21.30 +0.5%	$18.93	$7.48 ▼ $29.82	$380.67M	1.29	220,366 shs	110,813 shs
SVRA Savara	$2.26 +2.7%	$2.84	$1.89 ▼ $5.11	$390.61M	0.32	1.43 million shs	652,292 shs

Reduce the Risk

Market downturns give many investors pause, and for good reason. Wondering how to offset this risk? Enter your email address to learn more about using beta to protect your portfolio.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ETTX Entasis Therapeutics	0.00%	0.00%	0.00%	0.00%	0.00%
KMDA Kamada	-0.57%	+4.35%	+1.91%	-3.87%	+36.27%
RIGL Rigel Pharmaceuticals	-1.72%	+3.16%	+13.86%	+6.43%	+107.75%
SVRA Savara	-5.58%	-11.65%	-27.15%	-20.29%	-46.47%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
ETTX Entasis Therapeutics	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
KMDA Kamada	3.9323 of 5 stars	3.4	3.0	0.0	0.0	3.0	1.7	3.1
RIGL Rigel Pharmaceuticals	3.288 of 5 stars	3.2	2.0	0.0	0.0	4.1	1.7	1.9
SVRA Savara	2.2534 of 5 stars	3.3	1.0	0.0	0.0	1.9	3.3	0.6

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ETTX Entasis Therapeutics	0.00	N/A	N/A	N/A
KMDA Kamada	2.75	Moderate Buy	$14.67	111.34% Upside
RIGL Rigel Pharmaceuticals	2.40	Hold	$36.40	70.89% Upside
SVRA Savara	2.67	Moderate Buy	$7.17	217.11% Upside

Current Analyst Ratings Breakdown

Latest ETTX, SVRA, KMDA, and RIGL Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
5/29/2025	SVRA Savara	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Buy ➝ Neutral	$6.00 ➝ $2.00
5/28/2025	SVRA Savara	Evercore ISI Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	In-Line ➝ In-Line	$3.00 ➝ $2.00
5/28/2025	SVRA Savara	Guggenheim Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$9.00 ➝ $8.00
5/28/2025	SVRA Savara	Wells Fargo & Company Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Overweight ➝ Overweight	$8.00 ➝ $7.00
5/15/2025	KMDA Kamada	Benchmark Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$15.00 ➝ $15.00
5/8/2025	KMDA Kamada	Sidoti Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Hold
5/7/2025	RIGL Rigel Pharmaceuticals	Cantor Fitzgerald Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Neutral ➝ Neutral	$20.00 ➝ $23.00
3/28/2025	SVRA Savara	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$6.00 ➝ $6.00
3/21/2025	KMDA Kamada	Benchmark Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy	$15.00

(Data available from 6/12/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ETTX Entasis Therapeutics	$7M	14.97	N/A	N/A	$0.66 per share	3.32
KMDA Kamada	$167.24M	2.39	$0.39 per share	17.90	$4.25 per share	1.63
RIGL Rigel Pharmaceuticals	$203.08M	1.87	N/A	N/A	($1.64) per share	-12.99
SVRA Savara	N/A	N/A	N/A	N/A	$1.04 per share	N/A

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ETTX Entasis Therapeutics	-$47.14M	-$1.12	N/A	N/A	N/A	N/A	-145.48%	-103.75%	N/A
KMDA Kamada	$8.28M	$0.29	24.79	21.69	0.97	9.92%	6.30%	4.49%	8/13/2025 (Estimated)
RIGL Rigel Pharmaceuticals	-$25.09M	$2.07	152.15	20.29	N/A	2.46%	-14.80%	3.03%	8/5/2025 (Estimated)
SVRA Savara	-$54.70M	-$0.48	N/A	N/A	N/A	N/A	-58.89%	-46.44%	8/11/2025 (Estimated)

Latest ETTX, SVRA, KMDA, and RIGL Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
5/14/2025	Q1 2025	KMDA Kamada	$0.07	$0.07	N/A	$0.07	$154.06 million	$44.02 million
5/13/2025	Q1 2025	SVRA Savara	-$0.12	-$0.12	N/A	-$0.12	N/A	N/A
5/6/2025	Q1 2025	RIGL Rigel Pharmaceuticals	$0.14	$0.63	+$0.49	$0.63	$43.87 million	$53.33 million
3/27/2025	Q4 2024	SVRA Savara	-$0.11	-$0.13	-$0.02	-$0.13	N/A	$0.27 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
ETTX Entasis Therapeutics	N/A	N/A	N/A	N/A	N/A
KMDA Kamada	N/A	N/A	N/A	N/A	N/A
RIGL Rigel Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
SVRA Savara	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ETTX Entasis Therapeutics	N/A	1.65	1.65
KMDA Kamada	N/A	4.84	2.73
RIGL Rigel Pharmaceuticals	N/A	1.96	1.87
SVRA Savara	0.13	17.70	17.70

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ETTX Entasis Therapeutics	6.91%
KMDA Kamada	20.38%
RIGL Rigel Pharmaceuticals	66.23%
SVRA Savara	87.93%

Insider Ownership

Company	Insider Ownership
ETTX Entasis Therapeutics	6.50%
KMDA Kamada	36.10%
RIGL Rigel Pharmaceuticals	9.48%
SVRA Savara	5.33%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ETTX Entasis Therapeutics	51	47.85 million	44.74 million	Not Optionable
KMDA Kamada	360	57.51 million	36.73 million	Optionable
RIGL Rigel Pharmaceuticals	160	17.87 million	16.02 million	Optionable
SVRA Savara	N/A	172.84 million	162.82 million	Optionable

ETTX, SVRA, KMDA, and RIGL Headlines

Recent News About These Companies

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Savara Inc. - SVRA

June 12 at 9:00 AM | prnewswire.com

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Savara Inc. - SVRA

June 11 at 9:00 AM | accessnewswire.com

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Savara Inc. - SVRA

June 9 at 12:45 PM | accessnewswire.com

savara elects board members and approves proposals at annual meeting

June 8, 2025 | investing.com

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Savara Inc. - SVRA

June 7, 2025 | prnewswire.com

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Savara Inc. - SVRA

June 6, 2025 | globenewswire.com

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Savara Inc. - SVRA

June 5, 2025 | accessnewswire.com

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Savara Inc. - SVRA

June 4, 2025 | accessnewswire.com

Millennium Management LLC Grows Stake in Savara Inc (NASDAQ:SVRA)

June 4, 2025 | marketbeat.com

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Savara Inc. - SVRA

June 3, 2025 | accessnewswire.com

Joseph S. Mccracken Acquires 10,000 Shares of Savara Inc (NASDAQ:SVRA) Stock

June 3, 2025 | insidertrades.com

HC Wainwright Has Negative Outlook of Savara FY2026 Earnings

June 3, 2025 | americanbankingnews.com

Savara assumed with an Outperform at Oppenheimer

June 2, 2025 | msn.com

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Savara Inc. - SVRA

June 2, 2025 | globenewswire.com

Savara Inc (NASDAQ:SVRA) Director Joseph S. Mccracken Acquires 10,000 Shares

June 2, 2025 | marketbeat.com

Wellington Management Group LLP Reduces Stock Holdings in Savara Inc (NASDAQ:SVRA)

June 2, 2025 | marketbeat.com

What is HC Wainwright's Forecast for Savara FY2026 Earnings?

June 2, 2025 | marketbeat.com

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Savara Inc. - SVRA

June 1, 2025 | gurufocus.com

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Savara Inc. - SVRA

June 1, 2025 | prnewswire.com

Two Sigma Investments LP Boosts Stake in Savara Inc (NASDAQ:SVRA)

June 1, 2025 | marketbeat.com

Savara Inc (NASDAQ:SVRA) Receives Average Recommendation of "Moderate Buy" from Brokerages

June 1, 2025 | marketbeat.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

ETTX, SVRA, KMDA, and RIGL Company Descriptions

Entasis Therapeutics NASDAQ:ETTX

Entasis Therapeutics Holdings Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of antibacterial products to treat serious infections caused by multidrug-resistant pathogens in the United States. Its lead product candidate is sulbactam-durlobactam (SUL-DUR), a novel IV antibiotic that is in Phase III clinical trial for the treatment of pneumonia and bloodstream infections caused by carbapenem-resistant Acinetobacter baumannii. The company also develops Zoliflodacin, a novel orally administered molecule, which is in Phase III clinical trial for the treatment of uncomplicated gonorrhea; ETX0282CPDP, an oral drug that is in Phase I clinical trial for the treatment of urinary tract infections; and ETX0462, a drug candidate from NBP platform that is in pre-clinical stage for the treatment of multidrug-resistant gram-negative infections. The company has a license and collaboration agreement with Zai Lab (Shanghai) Co., Ltd. for the development of durlobactam and SUL-DUR; and collaboration agreement with Global Antibiotic Research and Development Partnership for the development and commercialization of a product candidate zoliflodacin. Entasis Therapeutics Holdings Inc. was founded in 2015 and is headquartered in Waltham, Massachusetts. Entasis Therapeutics Holdings Inc. operates as a subsidiary of Innoviva, Inc.

Kamada NASDAQ:KMDA

$6.94 -0.01 (-0.14%)

As of 04:00 PM Eastern

Kamada Ltd. manufactures and sells plasma-derived protein therapeutics. Its commercial products include KAMRAB/KEDRAB for treating prophylaxis of rabies; CYTOGAM for Prophylaxis of Cytomegalovirus disease in kidney, lung, liver, pancreas, heart, and heart/lung transplants; VARIZIG for post exposure prophylaxis of varicella; WINRHO SDF for immune thrombocytopenic purpura and suppression of rhesus isoimmunization; HEPAGAM B for prevention of hepatitis B recurrence liver transplants and post-exposure prophylaxis; GLASSIA for intravenous AATD; KAMRHO (D) IM for prophylaxis of hemolytic disease of newborns; KAMRHO (D) IV for immune thermobocytopunic purpura; and Echis coloratus and Vipera palaestinae Antiserum for the treatment of snake bite. The company also distributes imported drug products in Israel, including BRAMITOB to manage chronic pulmonary infection; FOSTER to treat asthma; TRIMBOW for chronic obstructive pulmonary disease; PROVOCHOLINE for the diagnosis of bronchial airway hyperactivity; AEROBIKA, an OPEP device; RUPAFIN and RUPAFIN ORAL SOLUTION for allergic rhinitis and Urticaria; SINTREDIUS for rheumatoid arthritis, systemic lupus erythematosus, and mild-moderate juvenile dermatomyositis; IVIG for immunodeficiency-related conditions; VARITECT for chicken pox and zoster herpes; ZUTECTRA and HEPATECT CP for hepatitis B; MEGALOTECT CP for CMV virus; RUCONEST for angioedema attack; HEPARIN SODIUM INJECTION for thrombo-embolic disorders and prophylaxis of deep vein thrombosis and thromboembolic events; ALBUMIN and ALBUMIN for blood plasma; Factor VIII for hemophilia type A; and Factor IX for hemophilia type B. In addition, it distributes COAGADEX for hereditary factor X deficiency; IXIARO for Japanese encephalitis; VIVOTIF for Salmonella Typhi; PROCYSBI for nephropathic cystinosis; LAMZEDE for alpha-mannosidosis; ELIGARD for prostate cancer; and BEVACIZUMAB KAMADA for various cancers. The company was incorporated in 1990 and is headquartered in Rehovot, Israel.

Rigel Pharmaceuticals NASDAQ:RIGL

$21.30 +0.11 (+0.52%)

As of 04:00 PM Eastern

Rigel Pharmaceuticals, Inc., a biotechnology company, engages in discovering, developing, and providing therapies that enhance the lives of patients with hematologic disorders and cancer. The company's commercialized products include Tavalisse, an oral spleen tyrosine kinase inhibitor for the treatment of adult patients with chronic immune thrombocytopenia; Rezlidhia, a non-intensive monotherapy for the treatment of adult patients with relapsed or refractory (R/R) acute myeloid leukemia (AML) with a susceptible isocitrate dehydrogenase-1 (IDH1) mutation as detected by an FDA-approved test; and GAVRETO, a once daily, small molecule, oral, kinase inhibitor for the treatment of adult patients with metastatic rearranged during transfection (RET) fusion-positive non-small cell lung cancer, as well as for the treatment of adult and pediatric patients 12 years of age and older with advanced or metastatic RET fusion-positive thyroid cancer. It also develops R289, an oral IRAK1/4 Inhibitor, which is in Phase 1b clinical trials for the treatment of hematology-oncology, autoimmune, and inflammatory diseases; and a receptor-interacting serine/threonine-protein kinase 1 (RIPK1) inhibitor program in clinical development with partner Eli Lilly and Company. In addition, the company has product candidates in clinical development with partners BerGenBio ASA and Daiichi Sankyo. The company has strategic development collaboration with The University of Texas MD Anderson Cancer Center for the development of REZLIDHIA (Olutasidenib) in acute myeloid leukemia (AML) and other hematologic cancers. The company was incorporated in 1996 and is headquartered in South San Francisco, California.

Savara NASDAQ:SVRA

$2.26 +0.06 (+2.73%)

As of 04:00 PM Eastern

Savara Inc., formerly Mast Therapeutics, Inc., is a clinical-stage pharmaceutical company. The Company is focused on the development and commercialization of novel therapies for the treatment of patients with rare respiratory diseases. Its pipeline includes AeroVanc, Molgradex and AIR001. AeroVanc is an inhaled formulation of vancomycin, which the Company is developing for the treatment of persistent methicillin-resistant Staphylococcus aureus, lung infection in cystic fibrosis patients. Molgradex is an inhaled formulation of recombinant human granulocyte-macrophage colony-stimulating factor. It is developing Molgradex for the treatment of autoimmune pulmonary alveolar proteinosis, a rare lung disease. AIR001 is a sodium nitrite solution for inhalation via nebulization. AIR001 is in Phase II clinical development for the treatment of heart failure with preserved ejection fraction, also known as diastolic heart failure or heart failure with preserved systolic function.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time